Polymers with inherent pharmacologic activity has captured recent attention as suitable components of drug delivery systems for combination cancer therapies. Chemokine networks control cell movement to specific locations throughout the body as part of normal homeostasis and during pathological processes such as cancer and inflammation. In tumors, a complex chemokine network controls cell trafficking into and out of the tumor microenvironment. Importantly, chemokine networks are directly involved in the molecular control of metastasis and govern organ-specific homing of metastatic cells, which makes them promising targets for the development of antimetastatic therapies. We have developed a class of polymers (PCX) with inherent ability to inhibit the CXCR4 chemokine receptor and to deliver therapeutic nucleic acids as part of combination antimetastatic therapies. I will present our progress towards development of fluorinated PCX/siRNA nanoparticles as antimetastatic therapies based on combined inhibition of CXCR4 and silencing of the signal transducer and activator of transcription 3 (STAT3) in metastatic breast cancer.

Polymers and polymer assemblies with inherent pharmacologic activity to target chemokine networks in the treatment of metastatic cancer

256th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.